Galderma drug passes PhIII in rare skin disease, setting the stage for approval request

Kyle LaHucik

Senior Reporter

Dermatology behemoth Galderma is one step closer to regulators’ doorsteps for a monoclonal antibody it licensed from Chugai Pharmaceutical after a Phase III readout Wednesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Galderma drug passes PhIII in rare skin disease, setting the stage for approval request

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Gal­der­ma drug pass­es PhI­II in rare skin dis­ease, set­ting the stage for ap­proval re­quest

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Galderma drug passes PhIII in rare skin disease, setting the stage for approval request